Hangzhou Sciwind Biosciences Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2017-08-17
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sciwind.com.cn
Clinical Trials
8
Active:0
Completed:6
Trial Phases
3 Phases
Phase 1:3
Phase 3:3
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (37.5%)Phase 3
3 (37.5%)Not Applicable
2 (25.0%)A Study of XW003 Injection in Chinese Adolescents With Obesity
Not Applicable
Not yet recruiting
- Conditions
- Obese AdolescentsObesity
- Interventions
- Drug: placebo with matching volume
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT07143227
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
Not Applicable
Recruiting
- Conditions
- ObesityWeight Management
- Interventions
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT07073417
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT06335134
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
Phase 3
Completed
- Conditions
- Weight Management
- Interventions
- Drug: Ecnoglutide Medium DosageDrug: PlaceboDrug: Ecnoglutide Low DosageDrug: Ecnoglutide High Dosage
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 664
- Registration Number
- NCT05813795
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT05779995
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
- Prev
- 1
- 2
- Next
News
No news found